Skip to main content
Triangle logo TriangleGet started

Sunitinib (CLOSED TO ENROLLMENT) (NCT02693535)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer: a one-minute explainerNCT026935351 min

Sunitinib (CLOSED TO ENROLLMENT) trial for Lymphoma, Non-Hodgkin (NCT02693535). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged twelve or older with advanced solid tumors, B-cell non-Hodgkin lymphoma or myeloma and a qualifying tumor marker. Standard treatment must generally be exhausted; drug-specific age limits apply. Primary brain tumors are excluded.

The idea: match treatment to tumor biology. Options remain futibatinib, dabrafenib with trametinib, or trastuzumab deruxtecan. These block growth signals or deliver toxins to marked cells. Older treatment groups are closed. Researchers assess cancer control and safety.

This phase 2 study plans 4200 patients. The American Society of Clinical Oncology sponsors 146 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.